{‘She has no qualifications’: this US scientific community girds for Tracy Beth Høeg’s role at the FDA.

While America continues making sweeping adjustments to its vaccination guidelines, a particular individual has emerged in a surprising turn: Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by questioning coronavirus shots throughout the global health crisis and has concentrated on alleged fatalities following Covid immunization in her short tenure at the FDA.

Planned Overhauls to Pediatric Vaccine Program

Agency leaders planned to unveil major revisions to the childhood immunization program earlier this month, bringing the US with Denmark’s vaccine program, it is understood – a significant shift that would place the US at odds with a large portion of the world with little proof for public health gain. The planned update has been pushed back until the coming year.

In place of the director of the vaccine center, Høeg is listed to present at the event. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this calendar year.

Consolidating Power at the Agency

The acting appointment may indicate a closer partnership between the drug and vaccine divisions as Dr. Høeg and Prasad consolidate power at the agency – and it suggests a renewed priority upon dismantling already-approved immunizations at the FDA.

Høeg has repeatedly called for ending specific childhood vaccine recommendations in the US so as to align more similar to Denmark, a nation with universal health coverage and a number of inhabitants roughly the size of Wisconsin’s.

So far comments, she has continued to focus on vaccines – traditionally the responsibility of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Doubts Over Qualifications

Høeg has no obvious experience in medication creation, oversight or management, which has been customary for previous leaders of the CBER. She has been employed at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in leading a sizeable institution. She is not an expert in industry regulation.”

Past heads of the center would “understand laws and regulations and the research of drug development”, said Dr. Janet Woodcock. “Frankly, she lacks the kind of background that prior appointees who headed CBER have had.”

CDER has an immense portfolio at the agency, Woodcock stated.

“Many people just focuses on the novel medication approvals, but the generic program approves numerous generic medications. There is also a biosimilars program, over-the-counter program and more, and every single one must be supervised,” she noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a significant administrative aspect to the position, which oversees more than 5,000 personnel. “It’s a huge management job, if you do it right,” Woodcock said.

Official Statement and Contentious Initiatives

Regarding inquiries about Dr. Høeg's qualifications and whether this selection represents more teamwork among FDA leaders on vaccines, a press secretary said that the “inquiries rely on incorrect presumptions”.

“This background aligns with the responsibilities of her role,” the representative explained, pointing to the months Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg inherits the commissioner’s recently launched fast-track approval initiative, a controversial expedited therapy clearance system that allegedly concerned her preceding directors. “How are these drugs being selected for this voucher program? Who makes the decisions?” Dr. Howard asked. “There is a lot of confidentiality occurring at the agency right now.”

Overall, he stated, “the FDA seems to be moving towards less stringent oversight of pharmaceuticals, aside from vaccines.”

Documented Track Record on Immunizations

Concerning immunizations, Høeg has a more established, if troubling, history, critics said. She published a analysis using unconfirmed public submissions to determine the rate of heart inflammation following COVID-19 vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccines are pose a greater threat than they are.

Included in her “desired changes” for the incoming federal leadership encompassed altering rules for recently developed shots and halting “unnecessary” vaccines, she remarked post-election on a audio program. At the agency, Dr. Høeg has allegedly proposed preventing young men from getting Covid vaccinations.

“She’s an complete ideologue who begins with her beliefs and reverse-engineers to retrofit the data in a very misleading, fraudulent way,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined fellow skeptics, {like|